Piscitelli S C, Kelly G, Walker R E, Kovacs J, Falloon J, Davey R T, Raje S, Masur H, Polis M A
Department of Pharmacy, National Institute of Allergy and Infectious Diseases, National Institutes of Health, Bethesda, Maryland 20892-1196, USA.
Antimicrob Agents Chemother. 1999 Mar;43(3):647-50. doi: 10.1128/AAC.43.3.647.
The effects of multiple opportunistic infection medications on stavudine pharmacokinetics were evaluated. Ten patients with CD4 counts of less than 200 cells/mm3 received stavudine (40 mg twice daily) in combination with one to three other drugs used to treat opportunistic infections. Serial blood samples for stavudine concentrations were collected after 1 week of therapy on each regimen and assayed for stavudine by using a validated high-pressure liquid chromatography method. Although the maximum concentration of drug in serum was significantly decreased when the drug was given in combination with three opportunistic infection medications, the area under the concentration-time curve did not significantly differ across various treatment regimens. Stavudine exposure was not significantly altered by multiple concomitant medications. Side effects were minor throughout the 3-month study period. The tolerability of stavudine, combined with its lack of drug interactions, makes it an attractive agent for use as part of a combination regimen.
评估了多种抗机会性感染药物对司他夫定药代动力学的影响。10例CD4细胞计数低于200个/mm³的患者接受司他夫定（每日两次，每次40mg），并联合使用一至三种其他用于治疗机会性感染的药物。在每种治疗方案治疗1周后采集系列血样检测司他夫定浓度，并用经过验证的高压液相色谱法测定司他夫定。虽然当司他夫定与三种抗机会性感染药物联用时血清中药物的最大浓度显著降低，但不同治疗方案的浓度-时间曲线下面积并无显著差异。多种伴随用药并未显著改变司他夫定的暴露量。在整个3个月的研究期间，副作用较小。司他夫定的耐受性及其不存在药物相互作用，使其成为联合治疗方案中颇具吸引力的一种药物。
